Overview
Registration
Agenda
Eaccme Accreditation
Faculty
View Archive

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS). European physicians can earn their ECMEC®s by attending live events worldwide, except in Europe, that have been certified for AMA PRA Category 1 Credits™.

For further information on reciprocity, please see the AMA website at https://www.ama-assn.org/education/ama-pra-credit-system/agreement-european-union-medical-specialties-uems.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo.

Targeting HER2/3 in Advanced NSCLC: Where Are We and Where Are We Going?

Targeting HER2/3 in Advanced NSCLC: Where Are We and Where Are We Going?


Tuesday, 16 June 2020

Live Webcasts:
20:00 – 21:30 CEST (2:00 – 3:00 PM EDT)
8:00 – 9:30 PM EDT

Overview

HER2 mutations have been identified as an oncogenic driver in non–small cell lung cancer (NSCLC). HER2 amplification is a mechanism of acquired resistance to first-generation TKIs in EGFR mutant-positive lung cancers. There has been progress in the development of EGFR-targeted therapies for lung cancers; however, intrinsic and acquired resistance remains a significant clinical challenge. Community clinicians who treat patients with HER2-altered NSCLC need to be up to date on the most accurate methods of diagnosis to effectively select frontline therapy and beyond to provide best practice care to their patients.

This live webcast will be presented by experts in NSCLC to discuss testing strategies for HER2 alterations in a clinically applicable manner. The expert panel will discuss current and emerging treatment options for HER2 alteration-positive NSCLC. Additionally, they will address challenges experienced by clinicians in daily practice and the management of adverse events relating to HER2-targeted treatment.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo.

Target Audience

These activities are intended for a global audience of medical oncologists, pathologists, and other healthcare professionals interested in the latest advances in the treatment of patients with NSCLC. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with NSCLC are also invited to attend.

Learning Objectives

Upon successful completion of this activity, participants will be better prepared to:

  • Explain the rationale for testing HER2/3 in patients with advanced NSCLC.
  • Outline molecular testing strategies for the detection of HER2/3 in advanced NSCLC.
  • Consider data from clinical trials exploring HER2/3 targeted treatment for patients with advanced NSCLC.
  • Evaluate novel treatment strategies for NSCLC patients with HER2/3 alterations.

Program Chair

Maurice Pérol, MD
Maurice Pérol, MD
Head of Thoracic Oncology Program
Department of Medical Oncology
Léon Bérard Cancer Center
Lyon, France




Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By